New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease
Abstract Cytomegalovirus (CMV) infection can have both direct and indirect effects after solid-organ transplantation, with a significant impact on transplant outcomes. Prevention strategies decrease the risk of CMV disease, although CMV still occurs in up to 50% of high-risk patients. Ganciclovir (G...
Main Authors: | Camille Nelson Kotton, Nassim Kamar |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2022-12-01
|
Series: | Infectious Diseases and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40121-022-00746-1 |
Similar Items
-
A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient
by: Helen Pearce, et al.
Published: (2024-01-01) -
Use of Letermovir for CMV Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: Review of the Literature and Single-Center Real-Life Experience
by: Jessica Gill, et al.
Published: (2023-04-01) -
Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
by: Léna Royston, et al.
Published: (2021-04-01) -
New Treatment Options for Refractory/Resistant CMV Infection
by: Carla Simone Walti, et al.
Published: (2023-10-01) -
Anti-CMV therapy, what next? A systematic review
by: Claire Gourin, et al.
Published: (2023-11-01)